Adrenomyeloneuropathy (AMN) is a rare hereditary disease that affects approximately 30,000 people worldwide. Even though most people have never heard of AMN, it continues to be a very important focus for Nutra Pharma’s drug development.

Our goal is to receive the approval to launch the first-ever treatment for AMN using our lead drug candidate for autoimmune and neurological disorders, RPI-78M. Almost a year and a half ago, we began a 15-month phase IIb/IIIa human clinical trial in London to help us better understand the efficacy of RPI-78M in treating AMN. Because patients started the trial at different times (we refer to this as a staggered start), the trial is now coming to a close.

One of the primary reasons we chose to focus on AMN is because its symptoms display very similar characteristics to those of Multiple Sclerosis (MS). Many who have followed Nutra Pharma over the years already know that we are researching a possible treatment for MS. Both AMN and MS are characterized by demyelination, or, the loss of the myelin sheath insulating the nerves.

Our previous clinical trial data has led us to believe that RPI-78M induces gamma-interferon and interleukin-27 (IL-27). Recently, IL-27 was discovered to be an important anti-inflammatory regulator in cells of the immune system and many scientists now believe that IL-27 helps reduce symptoms of MS. We feel this property is not isolated to MS, but extends into AMN as well.

As a side note, we filed a patent with the United States Patent office in April 2007 to protect our method of regulating IL-27 using modified cobratoxin.

Because we are just now completing our phase IIb/IIIa clinical trial for the treatment of AMN, we expect to have the data compiled by mid to late August. Once we finish reviewing this data, it will be released to the public and our shareholders.

In the meantime, here are some additional resources for learning more about Adrenomyeloneuropathy:

AMNhelp.com
An online resource published by Nutra Pharma about AMN

AMN Community on RareShare
An online community for people affected by AMN

United Leukodystrophy Foundation
A foundation dedicated to helping children and adults who have Leukodystrophy and assisting the family members, professionals and support services that serve them.

SEC Disclaimer
This article contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The Company's business is subject to various risks, which are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"). The above article, " Our Focus on Adrenomyeloneuropathy (AMN)", should not be construed as an indication in any way whatsoever of: (a) the Company’s financial value; and/or (b) any predictive value of the Company’s future stock price. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.

               

Comments

No comments yet.

RSS feed for comments on this post.

TrackBack URL

Leave a Comment

Name (required)

Email (will not be published) (required)

Website